Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mona Sabharwal"'
Autor:
Judy Truong, Kelvin K. W. Chan, Helen Mai, Alexandra Chambers, Mona Sabharwal, Maureen E. Trudeau, Matthew C. Cheung
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3770-3781 (2019)
Abstract Background The soaring costs of anti‐cancer drugs pose a threat to the sustainability of cancer care. The pricing strategy chosen by manufacturers can impact the costs of oral anti‐cancer drugs during dose modifications, but this issue r
Externí odkaz:
https://doaj.org/article/acad35d99541441ea5929c5f953bbbe0
Autor:
Maureen E. Trudeau, Matthew C. Cheung, Judy Truong, Helen Mai, Kelvin K. W. Chan, Alexandra Chambers, Mona Sabharwal
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3770-3781 (2019)
Cancer Medicine
Cancer Medicine
Background The soaring costs of anti‐cancer drugs pose a threat to the sustainability of cancer care. The pricing strategy chosen by manufacturers can impact the costs of oral anti‐cancer drugs during dose modifications, but this issue remains un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd2a9c8a64a942428718d9f5144d47d
https://doaj.org/article/acad35d99541441ea5929c5f953bbbe0
https://doaj.org/article/acad35d99541441ea5929c5f953bbbe0
Autor:
Erica McDonald, Mahin Iqbal Qureshi, Mona Sabharwal, Kelley-Anne Sabarre, Sierra Cheng, Vanessa Sarah Arciero, Natasha B. Leighl, Dolly Han, Doreen A. Ezeife, Matthew C. Cheung, Alexandra Chambers, Di Maria Jiang, Kelvin K. W. Chan
Publikováno v:
Journal of Clinical Oncology. 35:2764-2771
Purpose Whether the ASCO Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCBS) measure similar constructs of clinical benefit is unclear. It is also unclear how they relate to quality-adjusted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddf8d4bb0bbc155982b85143595ee1f7
https://doi.org/10.1200/jco.2016.71.6894
https://doi.org/10.1200/jco.2016.71.6894
Autor:
Alexandra Chambers, Jessa Letargo, Kelvin K. W. Chan, Helen Mai, Matthew C. Cheung, Maureen E. Trudeau, Mona Sabharwal, Judy Truong
Publikováno v:
Cancer. 123:3583-3590
BACKGROUND The objective of this study was to determine the impact of modeling cancer drug wastage in economic evaluations because wastage can result from single-dose vials on account of body surface area– or weight-based dosing. METHODS Intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5db6e758d913cad77497fbb091556f50
https://doi.org/10.1002/cncr.30807
https://doi.org/10.1002/cncr.30807
Autor:
Matthew C. Cheung, Mona Sabharwal, Kelvin K. W. Chan, Alexandra Chambers, William K. Evans, Anthony Fields
Publikováno v:
The Lancet Oncology. 18:573-575
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930823e106deea9fd6cd58d0f3a27ba3
https://doi.org/10.1016/s1470-2045(17)30266-8
https://doi.org/10.1016/s1470-2045(17)30266-8
Publikováno v:
Masucci, L; Beca, J; Sabharwal, M; & Hoch, JS. (2017). Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).. PharmacoEconomics-open, 1(4), 255-263. doi: 10.1007/s41669-017-0018-3. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/53n215fm
PharmacoEconomics-open, vol 1, iss 4
PharmacoEconomics Open
PharmacoEconomics-open, vol 1, iss 4
PharmacoEconomics Open
Background Public drug plans are faced with increasingly difficult funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) makes funding recommendations to the provincial and territorial drug plans responsible for cancer drugs. As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c3496a7a6a27b0150361a785d7d6d23
http://www.escholarship.org/uc/item/53n215fm
http://www.escholarship.org/uc/item/53n215fm
Publikováno v:
Pharmacoeconomics
PharmacoEconomics DOI 10.1007/s40273-015-0278-7 LETTER TO THE EDITOR Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? Jeffrey S. Hoch 1,2,3,4 • Jaclyn Beca 1,2,3 • Mona Sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c48abff6b03b5504af642e36521240
https://doi.org/10.1007/s40273-015-0278-7
https://doi.org/10.1007/s40273-015-0278-7
Autor:
Judy, Truong, Matthew C, Cheung, Helen, Mai, Jessa, Letargo, Alexandra, Chambers, Mona, Sabharwal, Maureen E, Trudeau, Kelvin K W, Chan
Publikováno v:
Cancer. 123(18)
The objective of this study was to determine the impact of modeling cancer drug wastage in economic evaluations because wastage can result from single-dose vials on account of body surface area- or weight-based dosing.Intravenous chemotherapy drugs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::362183737d9974c950d1d9defb65e979
https://pubmed.ncbi.nlm.nih.gov/28640359
https://pubmed.ncbi.nlm.nih.gov/28640359
Autor:
Mona Sabharwal, Jeffrey S Hoch
Publikováno v:
Current Oncology. 20:121-124
JSH: In July 2011, the pan-Canadian Oncology Drug Review [pcodr (http://www.pcodr.ca/)] began accepting submissions by pharmaceutical manufacturers and clinician-based tumour groups to have cancer drugs reimbursed by provincial payers in Canada. Does
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c420db4d21ce9df5d3898e45484de4b3
https://doi.org/10.3747/co.20.1315
https://doi.org/10.3747/co.20.1315
Autor:
Mona Sabharwal, Kelvin K. W. Chan, Anthony Fields, Alexandra Chambers, Matthew C. Cheung, William K. Evans
Publikováno v:
ESMO Open
The increasing burden of costs associated with novel cancer therapies is becoming untenable. In Europe and Canada, assessment frameworks have been developed to attribute value to novel therapies and ultimately facilitate access to cancer drug funding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d26f893ea643c93047fcf84a4a466c
https://pubmed.ncbi.nlm.nih.gov/29209520
https://pubmed.ncbi.nlm.nih.gov/29209520